The effects of two DNA aptamers (oligonucleotides) 15TBA and 31TBA (15- and 31-mer thrombin-binding aptamers, respectively) on thrombin activity were studied. Both aptamers added to human plasma dose-dependently increased thrombin time (fibrin formation upon exposure to exogenous thrombin), prothrombin time (clotting activation by the extrinsic pathway), and activated partial thromboplastin time (clotting activation by the intrinsic pathway). At the same time, these aptamers did not modify amidolytic activity of thrombin evaluated by cleavage of synthetic chromogenic substrate. Aptamers also inhibited thrombin-induced human platelet aggregation. The inhibitory effects of 31TBA manifested at lower concentrations than those of 15TBA in all tests. These data indicate that the studied antithrombin DNA aptamers effectively suppress its two key reactions, fibrin formation and stimulation of platelet aggregation, without modifying active center of the thrombin molecule.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-009-0627-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression.
Neoplasia
March 2025
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye. Electronic address:
Philadelphia chromosome-negative myeloproliferative neoplasms (PhMPNs) are clonal disorders marked by high morbidity and mortality, driven by uncontrolled myeloid proliferation from hematopoietic stem/progenitor cells (HSCs) and associated with a significant risk of thrombosis. This study explored the relationship between JAK2V617F and protease-activated receptor 1 (PAR1) by examining PAR1 expression and activation across various hematopoietic stem/progenitor cell (HSPC) subgroups, assessing their contribution to the hypercoagulable state in PhMPNs. We investigated the effects of thrombin, a PAR1 antagonist (vorapaxar), and a JAK2 inhibitor (ruxolitinib) on PhMPN cells.
View Article and Find Full Text PDFThe derivatives of hirudin-like peptides from the Poecilobdella manillensis exhibit antithrombotic and anti-ischemic stroke effects.
Int J Biol Macromol
March 2025
Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), State Key Laboratory of Genetic Evolution & Animal Models, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, the Chinese Academy of Sciences, No.17 Longxin Road, Kunming, Yunnan 650201, China. Electronic address:
Almost all currently approved anticoagulants interfere with hemostasis and increase the risk of bleeding complications. Thus, there is a critical need for safer anti-thrombotic drugs without bleeding risk. Hirudin has demonstrated potent antithrombotic properties, but is clinically limited due to its high bleeding risk.
View Article and Find Full Text PDFThe preclinical profile of SerpinPC- a potential new treatment for hemophilia.
Blood Adv
March 2025
Cambridge University Hospitals NHS Foundation Trust, Cambridge, ENG, United Kingdom.
The concept of restoring hemostasis by down-tuning anticoagulant pathways holds the promise of treating all forms of hemophilia. Here we report preclinical efficacy and safety data for SerpinPC, a covalent inhibitor of activated protein C (APC). APC is a serine protease that degrades the enzyme complex that produces thrombin, and its inhibition allows more thrombin to be produced during the initiation stage of hemostasis.
View Article and Find Full Text PDFThrombin-antithrombin complex might be a promising parameter for monitoring anticoagulation in the early postoperative period after LVAD implantation.
Lab Med
March 2025
Department of Laboratory Medicine, Sichuan Clinical Research Center for Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Introduction: Appropriate bridging anticoagulation is critical in the early postoperative period after left ventricular assist device (LVAD) implantation, because the patients are usually in a fragile balance of thrombotic to bleeding risk. Unfortunately, the ideal manner of monitoring postoperative bridging anticoagulation remains undetermined.
Methods: Here we reported a case demonstrating that thrombin-antithrombin complex might be an option in this situation.
Precise Identification of Inhibitors for Coagulation Reactions from Complex Extracts through Monitoring of Biological Aggregates Combined with a Targeted Fishing Technique.
Anal Chem
March 2025
Department of Pharmaceutical Analysis, School of Pharmacy, Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Ningxia Medical University, Yinchuan 750004, China.
Biological aggregates play a crucial role in the pathogenesis of thrombotic diseases, especially thrombin-induced biological aggregates. Therefore, the efficient discovery of thrombin inhibitors is of great significance for the prevention and treatment of thrombotic diseases. In this study, the aggregation precursor protein fluorescent probe was successfully prepared for monitoring the production of biological aggregates induced by thrombin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!